

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THIS STUDY AND ITS IMPORTANCE	1
INTENDED AUDIENCE.....	2
SCOPE AND FORMAT OF REPORT	2
METHODOLOGY AND INFORMATION SOURCES.....	2
ANALYST CREDENTIALS.....	3
BCC ONLINE SERVICES.....	3
DISCLAIMER	4
 CHAPTER TWO: EXECUTIVE SUMMARY.....	 5
SCOPE OF THE INDUSTRY	5
DRUG-DEVICE COMBINATIONS: THE GLOBAL MARKET.....	5
TECHNOLOGY AND PATENT ACTIVITY	6
THE CENTRAL ROLE OF THE FDA	6
<i>SUMMARY TABLE SALES OF DRUG DEVICE COMBINATION</i>	
<i>PRODUCTS, THROUGH 2014 (\$ BILLIONS)</i>	7
<i>SUMMARY FIGURE SALES OF DRUG DEVICE COMBINATION</i>	
<i>PRODUCTS, 2008-2014 (\$ BILLIONS)</i>	8
 CHAPTER THREE: CURRENT STATUS OF THE DRUG DEVICE	
COMBINATION INDUSTRY	9
OVERVIEW.....	9
ROLE OF THE FDA	9
<i>TABLE 1 RECENT EXAMPLES OF FDA APPROVED COMBINATION</i>	
<i>PRODUCTS</i>	10
<i>TABLE 1 (CONTINUED)</i>	11
OFFICE OF COMBINATION PRODUCTS ORGANIZATIONAL	
STRUCTURE.....	11
HIGHLY ADVANCED TECHNOLOGIES ARE A MARKET CORE	11
EXAMPLES OF THE MOST PATH-BREAKING PRODUCTS.....	12
FDA CLASSIFICATION SCHEME FOR INDIVIDUAL SEGMENTS	13
<i>TABLE 2 FDA CLASSIFICATION SCHEME FOR COMBINATION</i>	
<i>PRODUCTS</i>	14
THE RELATION BETWEEN NANOTECHNOLOGY AND	
COMBINATION PRODUCTS.....	14
FDA TRENDS IN REVIEWING COMBINATION PRODUCTS.....	14
<i>FIGURE 1 COMBINATION PRODUCT APPLICATIONS AT FDA, 2003-</i>	
<i>2007 (NUMBER OF SUBMISSIONS)</i>	15
<i>TABLE 3 FDA COMBINATION PRODUCT CATEGORIES, FY 2004</i>	16
<i>TABLE 4 FDA COMBINATION PRODUCT CATEGORIES, FY 2005</i>	
<i>(NUMBERS AND TYPES OF COMBINATION PRODUCTS)</i>	17
 CHAPTER FOUR: REGULATORY PROCESS AND ISSUES	 18

OVERVIEW.....	18
SCOPE OF FDA ACTION	18
TREATMENT OF DEVICES.....	19
CLASS I DEVICES	19
CLASS II DEVICES.....	19
CLASS III DEVICES	20
CURRENT STATUS OF FDA AND NANOTECHNOLOGY INITIATIVES.....	21
FDA NANOTECH PRODUCT APPROVALS	21
OTHER RELEVANT HEALTH OR REGULATORY AGENCIES.....	22
TYPICAL REGULATORY MILESTONES IN COMBINATION PRODUCT APPROVALS	23
CLINICAL TRIALS	24
 CHAPTER FIVE: NANOTECH COMBINATION PRODUCTS.....	 25
OVERVIEW.....	25
NATIONAL NANOTECHNOLOGY INITIATIVE (NNI).....	25
NANOTECH REGULATORY ENVIRONMENT.....	26
NANOTECH REGULATORY ENVIRONMENT (CONTINUED)	27
COMBINATION NANOTECHNOLOGY PRODUCT RESEARCH.....	28
NANODIAMOND DRUG DEVICES FOR CANCER TREATMENT.....	29
NANOTECHNOLOGY-MAGNETISM COMBINATION IN TINY IMPLANTABLE DEVICE FOR DRUG DELIVERY	30
IMPLANTS USING CONDUCTING POLYMER NANOTUBES	31
CALCIUM PHOSPHATE NANOPARTICLES FOR DRUG DELIVERY.....	32
NANO-SCALE DELIVERY OPTIMIZES CHEMOTHERAPY REGIMES.....	33
DRUG INFUSED NANOPARTICLES	34
Drug Infused Nanoparticles (Continued)	35
ENCAPSULATION OF DRUG TREATMENTS IN NANOPARTICLES	36
SILICON NANOWIRES FOR DRUG DELIVERY	36
MINUTE ANTIBACTERIAL PARTICLES DESTROY DRUG- RESISTANT GERMS	37
BIODEGRADABLE CATIONIC CORE-SHELL NANOPARTICLES FOR CO-DELIVERY OF DRUGS AND GENES	38
STIMULI-SENSITIVE CORE-SHELL NANOPARTICLES FOR CANCER THERAPY.....	38
POLYMER-BASED NON-VIRAL GENE CARRIERS.....	39
POTENTIAL HEALTH EFFECTS: IMPACT ON NANO INDUSTRY	39
POTENTIAL HEALTH EFFECTS: ... (CONTINUED).....	40

<i>TABLE 5 REVENUES ATTRIBUTABLE TO NANOTECHNOLOGY-BASED DRUG-DEVICE COMBINATIONS, THROUGH 2014 \$ MILLIONS</i>	41
CHAPTER SIX: DRUG-ELUTING CORONARY STENTS	42
OVERVIEW	42
DEFINITION AND SIZE OF TARGET MARKET	42
<i>TABLE 6 MARKETS FOR CORONARY STENTS, THROUGH 2014 \$ BILLIONS</i>	43
STENT MARKET REINFORCED BY CURRENT RESEARCH FINDINGS	43
STENT MARKET REINFORCED ...(CONTINUED)	44
STENT MARKET REINFORCED ...(CONTINUED)	45
PRINCIPAL DRUG-ELUTED STENT PRODUCERS	46
STENT DESIGN	46
PRODUCT LINES	47
PRODUCT LINES (CONTINUED)	48
MECHANISM OF ACTION	49
DEVELOPMENT OF THE INDUSTRY	49
FDA REGULATORY ROLE WITH REGARD TO STENTS	49
FDA REGULATORY ROLE ... (CONTINUED)	50
<i>TABLE 7 EXAMPLES OF STENTS APPROVED FOR CLINICAL USE</i>	51
<i>TABLE 7 (CONTINUED)</i>	52
STENT PRODUCT INNOVATIONS AND R&D: BIOABSORBABLE STENTS	52
BIODEGRADABLE COATINGS	53
HYDROXYAPATITE COATINGS	53
Hydroxyapatite Coatings (Continued).....	54
MARKETS FOR STENT RELATED TECHNOLOGIES	55
LIPISCAN CORONARY IMAGING SYSTEM.....	55
LipiScan Coronary Imaging System (Continued)	56
CHAPTER SEVEN: PHOTODYNAMIC THERAPY.....	57
OVERVIEW.....	57
TREATMENT LIMITATIONS	57
TECHNOLOGY HISTORY.....	58
RECENT DEVELOPMENTS	58
SECOND GENERATION PDT SENSITIZERS.....	59
PDT MARKETS FOR CANCER.....	59
PDT MARKETS FOR MACULAR DEGENERATION.....	60
PDT MARKETS FOR PSORIASIS.....	61
TYPES OF UVB THERAPY FOR PSORIASIS.....	61
PUVA PHOTOCHEMOTHERAPY.....	62
TARGETED PHOTOTHERAPY (EXCIMER LASER)	62
OTHER MEDICAL APPLICATIONS	63

PDT MARKET GROWTH DRIVERS.....	63
EXAMPLE PDT PRODUCTS.....	64
VISUDYNE (NOVARTIS).....	64
LEVULAN.....	65
PHOTOFRIN (PORFIMER SODIUM).....	65
VISONAC.....	65
CEVIRA.....	66
LUMACAN.....	66
RESEARCH AND DEVELOPMENT.....	66
INTERVENTIONAL CARDIOLOGY.....	66
DERMATOLOGY.....	67
AUTOIMMUNE DISEASES.....	67
EQUIPMENT PRODUCERS.....	68
<i>TABLE 8 PHOTODYNAMIC THERAPY MARKETS, THROUGH 2014</i> <i>(\$BILLIONS).....</i>	<i>68</i>
 CHAPTER EIGHT: ANTIMICROBIALS AND OTHER MEDICAL DEVICE	
COATINGS.....	69
OVERVIEW: REGULATORY TREATMENT.....	69
DRIVING FORCE IN DEVELOPMENT OF ANTI-MICROBIALS.....	69
DRIVING FORCE IN ... (CONTINUED).....	70
MARKET CONTEXT AND PREVALENCE OF INFECTIONS.....	71
EXAMPLES OF USE.....	72
TRENDS IN FDA APPLICATIONS FOR ANTIMICROBIALS.....	73
<i>TABLE 9 REVENUES ATTRIBUTABLE TO ANTIMICROBIALS</i> <i>THROUGH 2014 (\$ BILLIONS).....</i>	<i>73</i>
ANTI-MICROBIAL AND OTHER MEDICAL DEVICE COATINGS.....	73
MARKET CATEGORIES FOR MEDICAL DEVICE COATINGS IN COMBINATION PRODUCTS.....	74
<i>TABLE 10 REVENUES ATTRIBUTABLE TO MEDICAL DEVICE</i> <i>COATINGS THROUGH 2014 (\$ MILLIONS).....</i>	<i>75</i>
EXAMPLE PRODUCTS.....	75
<i>TABLE 11 MEDICAL DEVICE PRODUCTS RELYING ON</i> <i>ANTIMICROBIAL COATINGS.....</i>	<i>75</i>
<i>TABLE 11 (CONTINUED).....</i>	<i>76</i>
 CHAPTER NINE: ANTIMICROBIAL CATHETERS.....	
MARKET OVERVIEW.....	77
APPLICATIONS.....	77
MARKET SIZE.....	78
CATHETER INNOVATIONS.....	78
ANTIMICROBIAL CATHETER CONCEPTS.....	79
EXAMPLE PRODUCTS.....	80
5-FLUOROURACIL-COATED CENTRAL VENOUS CATHETER.....	80

DRUG - DEVICE COMBINATION CATHETER LOCK/FLUSH SOLUTIONS	81
R&D INITIATIVES.....	81
DIALYSIS CATHETERS	81
URINARY CATHETERS	82
OTHER DELIVERY TECHNIQUES.....	83
<i>TABLE 12 CATHETER MARKET FORECASTS, BY PRODUCT TYPE, THROUGH 2014 (\$ BILLIONS)</i>	84
CHAPTER TEN: DRUG-ELUTING BEADS	85
OVERVIEW.....	85
EXAMPLE OF THERAPY	85
COMPANY ACTIVITY	85
COMPANY ACTIVITY (CONTINUED)	86
BEAD APPLICATIONS IN STROKE	87
BEAD APPLICATIONS IN ALLERGY AND ASTHMA ATTACKS.....	87
RECENT FDA APPROVALS.....	88
RECENT OVERSEAS APPROVALS	89
CLINICAL TRIALS	90
<i>TABLE 13 CURRENT CLINICAL TRIALS INVOLVING DRUG-ELUTING BEADS</i>	91
<i>TABLE 13 (CONTINUED)</i>	92
R&D AND OTHER NOVEL APPLICATIONS OF BEADS	93
USING FLUORESCENT SILICA BEADS TO DETECT MALIGNANT CERVICAL CELLS	93
ANTIBODY COATED MAGNETIC BEADS TO COMBAT INFECTION.....	94
FUMAGILLIN NANOPARTICLES.....	94
Fumagillin Nanoparticles (Continued).....	95
CONTROLLED DELIVERY OF TUMOR-KILLER DRUGS	96
POLYMERIC MICROCAPSULES	97
<i>TABLE 14 R&D AND REVENUES ATTRIBUTABLE TO DRUG-ELUTED BEADS, THROUGH 2014 (\$ MILLIONS)</i>	98
CHAPTER ELEVEN: BONE CEMENTS INCLUDING ANTIBIOTIC	99
OVERVIEW.....	99
EARLY HISTORY.....	100
APPLICATIONS	100
MARKET SIZE.....	101
COMPOSITION	101
EXAMPLE PRODUCTS	102
RELATED PRODUCTS: TYPES OF CERAMICS.....	103
ALPHA-BSM	104
BIOGRAN.....	104
BIO-OSS	104

BONESOURCE	105
CALCIGEN S.....	105
CEMENTS IN DENTAL APPLICATIONS: GLASS IONOMER	
CEMENTS	105
OTHER OSTEOCONDUCTIVE BONE GRAFT SUBSTITUTES	106
OTHER OSTEOCONDUCTIVE BONE ... (CONTINUED).....	107
CHAPTER TWELVE: BONE GRAFT SUBSTITUTES	108
OVERALL SIZE OF BONE GRAFT BUSINESS	108
BONE GRAFT SUBSTITUTES.....	109
ALLOGRAFT TISSUE	110
OTHER OSTEOCONDUCTIVE BONE-GRAFT SUBSTITUTES	111
HYDROGELS IN BONE GRAFTING	112
Composition and Method for Self-Assembly and	
Mineralization of Peptide Amphiphiles.....	113
Chondroitinase ABC I Polynucleotides.....	114
Transdiscal Administration of Cycline Compounds.....	114
Composition and Method for Preparing Biocompatible	
Surfaces	114
Spinal Mobility Preservation Apparatus Having an	
Expandable Membrane	115
OSTEOBIOLOGICS AND OSTEOINDUCTIVE GROWTH FACTORS	115
BONE GRAFTS.....	116
<i>TABLE 15 CHARACTERISTICS OF IDEAL BONE GRAFT MATERIAL.....</i>	<i>117</i>
<i>TABLE 16 BONE GRAFT PROCEDURE VOLUMES BY APPLICATION</i>	
<i>IN THE U.S., THROUGH 2014</i>	<i>118</i>
<i>TABLE 17 BONE GRAFT PROCEDURE VOLUMES BY TYPE OF</i>	
<i>GRAFT IN THE U.S., THROUGH 2014.....</i>	<i>118</i>
<i>TABLE 18 COMPARISON OF BONE GRAFT MATERIALS.....</i>	<i>119</i>
<i>TABLE 18 (CONTINUED).....</i>	<i>120</i>
<i>TABLE 19 TYPES OF SUBSTITUTE BONE GRAFTS</i>	<i>120</i>
<i>TABLE 19 (CONTINUED).....</i>	<i>121</i>
AUTOGRAFTS	121
BioSeed Grafts	121
Allografts.....	122
Allografts (Continued)	123
Allografts (Continued)	124
Deminerlized Bone Matrix Products	125
<i>TABLE 20 SELECTED DBM PRODUCT AND PERCENTAGE OF</i>	
<i>DEMINERALIZED BONE MATRIX</i>	<i>125</i>
Accell	126
AlphaGRAFT.....	126
Allomatrix	126
Grafton DBM.....	126
DBX	126

DynaBlast and DynaGraft-D.....	126
Graftech.....	127
Grafton	127
Opteform	127
OrthoBlast II.....	128
Osteofil	128
Solo Cervical Allograft.....	128
Xenografts	128
THE MARKET FOR ALLOGRAFTS.....	129
<i>TABLE 21 THE U.S. MARKET FOR PRECISION-MACHINED</i>	
<i>ALLOGRAFTS, THROUGH 2014 (\$ MILLIONS).....</i>	<i>129</i>
CELL-BASED BONE GRAFT SUBSTITUTES.....	130
FACTOR-BASED BONE GRAFT SUBSTITUTES.....	131
BONE MORPHOGENIC PROTEINS	132
InductOs.....	133
INFUSE Bone Graft	133
OP-1 Implant	133
CERAMIC-BASED BONE GRAFT SUBSTITUTES	134
TYPES OF CERAMICS	135
Alpha-BSM.....	135
BioGran.....	136
Bio-Oss	136
BoneSource	136
Calcigen S	136
Collagraft Strip Bone Graft Matrix	136
Conduit TCP Granules	137
IsoTis Products	137
Mimix Bone Substitute Material	138
Norian SRS	138
OsteoGraf.....	138
Osteoset.....	139
Osteostim Resorbable Bone Graft Substitute	139
PerioGlas.....	139
Pro Osteon Implant	139
Vitoss.....	139
POLYMER-BASED BONE GRAFT SUBSTITUTES	140
Cortoss.....	140
Healos.....	141
Immix Extenders and Immix CB.....	142
THE MARKET FOR BONE GRAFT PRODUCTS	142
<i>TABLE 22 THE WORLDWIDE MARKET FOR BONE REPLACEMENT</i>	
<i>PRODUCTS, THROUGH 2014 (\$ MILLIONS).....</i>	<i>143</i>
<i>TABLE 23 THE U.S. MARKET FOR BONE REPLACEMENT</i>	
<i>PRODUCTS, THROUGH 2014 (\$ MILLIONS).....</i>	<i>143</i>

REGENERATIVE MEDICINE PRODUCTS IN DEVELOPMENT FOR	
BONE APPLICATIONS	144
BIOLOGIC/SYNTHETIC GRAFTS	144
CHRYSALIN	145
Chrysalin (Continued)	146
CHAPTER THIRTEEN: WOUND CARE PRODUCTS INCLUDING	
BIOLOGICAL DRESSINGS	147
WOUND CARE GENERALLY	147
MARKET SEGMENTS	147
COLLAGEN	147
COLLAGEN IN MEDICAL APPLICATIONS.....	148
<i>TABLE 24 IDENTIFICATION OF COLLAGEN-BASED PRODUCTS</i>	149
SPECIFIC COLLAGEN PRODUCTS	149
TenoMend™ Collagen Tendon Wrap.....	150
CosmoDerm and CosmoPlast Human-Based Collagen.....	150
TISSUE ENGINEERING	150
SKIN SUBSTITUTES: CELLS AND TISSUES	150
ARTIFICIAL SKIN	151
<i>TABLE 25 EXAMPLES OF SKIN SUBSTITUTE PRODUCTS</i>	152
SKIN-LIKE TISSUE DEVELOPED FROM HUMAN	
EMBRYONIC STEM CELLS	153
<i>TABLE 26 TOTAL SALES OF ENGINEERED SKIN GRAFTS AND</i>	
<i>REPLACEMENTS, THROUGH 2014 (\$ MILLIONS)</i>	154
ALGINATES.....	155
<i>TABLE 27 EXAMPLES OF ALGINATE-BASED PRODUCTS</i>	155
FIBRIN SEALANT PRODUCTS	156
HISTORY OF FIBRIN SEALANTS	156
PRODUCTS	157
Evicel	157
Artiss	157
ReCell	158
RELATED PRODUCTS: FIRST FDA APPROVED SPINE	
SEALANT.....	158
ENZYMATIC DEBRIDING AGENTS.....	159
NANOSTRUCTURED TEMPERATURE-SENSITIVE	
MEMBRANES FOR WOUND HEALING AND CELL	
GRAFTING	159
<i>TABLE 28 EXAMPLE ENZYMATIC DEBRIDING AGENTS</i>	160
<i>TABLE 29 MARKETS FOR BIOLOGICAL WOUND CARE PRODUCTS</i>	
<i>THROUGH 2014 (\$ BILLIONS)</i>	160
CHAPTER FOURTEEN: DRUG DEVICE COMBINATION PRODUCTS	
FOR OCCULAR APPLICATIONS.....	161
OVERVIEW.....	161

INTRAOCULAR LENS PRODUCTS.....	161
LENS MATERIALS	162
CLEAR LENS EXTRACTION AND REPLACEMENT (CLEAR)	
SURGERY	163
VITREOUS SUBSTITUTES.....	163
Polymers.....	164
Perfluorocarbon Liquids (PFCL).....	164
Silicone Oil.....	165
Combination Product: PFCL and Silicone Oil.....	165
OCULAR DRUG DELIVERY VIA NANOSTRUCTURED	
DRUG-LOADED CONTACT LENSES	166
MARKET POTENTIAL	167
<i>TABLE 30 MARKETS FOR OCCULAR APPLICATIONS IN DRUG-</i>	
<i>DEVICE COMBINATION PRODUCTS, THROUGH 2014 (\$</i>	
<i>MILLIONS).....</i>	<i>167</i>
CHAPTER FIFTEEN: IMPLANTABLES AS DRUG DEVICE	
COMBINATIONS.....	168
MINIATURE NEUROSTIMULATORS	168
BIODEGRADABLE CIRCUITS	168
BIODEGRADABLE CIRCUITS (CONTINUED).....	169
STEROID ELUTING PACEMAKER LEADS.....	170
MARKET SIZE.....	171
<i>TABLE 31 IMPLANTABLE DRUG DEVICE COMBINATIONS</i>	
<i>THROUGH 2014 (\$ MILLIONS).....</i>	<i>171</i>
CHAPTER SIXTEEN: RELATED DRUG DEVICE COMBINATIONS OF	
RELEVANCE	172
OVERVIEW.....	172
MARKET SIZE.....	172
<i>TABLE 32 MARKETS FOR RELATED DRUG-DEVICE COMBINATION</i>	
<i>PRODUCTS, THROUGH 2014 (\$ MILLIONS).....</i>	<i>172</i>
INJECTABLE BIODEGRADABLE HYDROGELS FOR DRUG	
DELIVERY AND TISSUE ENGINEERING	173
RADIATION/DRUG COMBINATIONS.....	173
ANTI-BACTERIAL RELEASING DENTAL RESTORATIVE	
MATERIALS.....	174
COMBINATION DENTAL PROPHYLAXIS PASTES AND DRUG	
COMPONENTS	174
METERED DOSE INHALERS, SPACERS AND OTHER	
ACCESSORIES.....	175
METERED DOSE INHALERS, ...(CONTINUED).....	176
ANTIMICROBIAL SUTURES	177
ANTIMICROBIAL VASCULAR GRAFTS.....	178
HEAT-ACTIVATED DRUGS	178

HEAT-ACTIVATED DRUGS (CONTINUED)	179
BREATH TEST COMBINATION PRODUCTS.....	180
MYOCELL THERAPY BY BIOHEART, INC.....	180
OTHER NEW DRUG DELIVERY CONCEPTS	181
CHAPTER SEVENTEEN: PATENT ANALYSIS.....	182
OVERVIEW.....	182
OTHER INTELLECTUAL PROPERTY ISSUES.....	182
EXAMPLE DRUG-DEVICE COMBINATION PATENTS: 2008 TO 2009	183
ELECTROPROCESSED COLLAGEN AND TISSUE ENGINEERING.....	183
BIOFUNCTIONAL, ANTIMICROBIAL COATINGS FOR MEDICAL DEVICES.....	183
GELATIN DERIVATIVES AND HIGH-MOLECULAR MICELLE COMPRISING THE DERIVATIVES.....	184
METHODS AND APPARATUS FOR ACUTE OR CHRONIC DELIVERY OF SUBSTANCES OR APPARATUS TO EXTRAVASCULAR TREATMENT SITES.....	185
WOUND COVERING.....	185
NANOPARTICLES FOR PROTEIN DRUG DELIVERY	186
PROCESS FOR PROVIDING ANTIMICROBIAL SURFACES.....	186
GROWTH FACTOR MODIFIED PROTEIN MATRICES FOR TISSUE ENGINEERING	186
METHOD OF COATING IMPLANTABLE MEDICAL DEVICES ...	187
ANTIMICROBIAL COATING FOR EROSION ENVIRONMENTS	187
METHOD AND COMPOSITION FOR PRODUCING CATHETERS WITH ANTIBACTERIAL PROPERTY.....	188
IMPLANTABLE MEDICAL DEVICE WITH ANTI-INFECTION AGENT	188
MINIATURE DRUG DELIVERY PUMP WITH A PIEZOELECTRIC DRIVE SYSTEM	189
IONTOPHORESIS DEVICE.....	189
APPARATUS FOR COATING MEDICAL DEVICES	189
COATINGS FOR DRUG DELIVERY DEVICES	190
THIN-FILM DRUG DELIVERY ARTICLE AND METHOD OF USE.....	190
IMPLANTABLE, TISSUE CONFORMING DRUG DELIVERY DEVICE.....	191
IMPLANTABLE DEVICE WITH RESERVOIRS FOR INCREASED DRUG LOADING	191
STENT ASSEMBLY FOR THE TREATMENT OF VULNERABLE PLAQUE.....	192

APPLICATION OF A THERAPEUTIC SUBSTANCE TO A TISSUE LOCATION USING AN EXPANDABLE MEDICAL DEVICE.....	192
MULTI-STABLE VALVES FOR MEDICAL APPLICATIONS AND METHODS FOR USE THEREOF	193
METHOD AND APPARATUS FOR DELIVERING COMBINED ELECTRICAL AND DRUG THERAPIES	193
HEPARIN PRODRUGS AND DRUG DELIVERY STENTS FORMED THEREFROM.....	194
NANOPARTICLE ASSEMBLED HOLLOW SPHERES.....	194
METHOD OF STENT MOUNTING TO FORM A BALLOON CATHETER HAVING IMPROVED RETENTION OF A DRUG DELIVERY STENT	195
STENT HAVING AN ULTRASONIC EMITTER	195
DRUG-ELUTING INTRAVASCULAR PROSTHESES AND METHODS OF USE	196
IMPLANTABLE DRUG DELIVERY DEVICE AND USE THEREOF	196
INTRA-AORTIC RENAL DELIVERY CATHETER.....	197
SYSTEM AND METHOD FOR DRUG DELIVERY AND MICROFLUIDIC APPLICATIONS USING MICRONEEDLES	197
ENCAPSULATED INORGANIC ANTIMICROBIAL ADDITIVE FOR CONTROLLED RELEASE.....	198
POLYMER NANOTECHNOLOGY	198

CHAPTER EIGHTEEN: INDUSTRY STRUCTURE AND COMPANY

PROFILES	199
OVERVIEW.....	199
REVENUES AND PROFITABILITY.....	199
COMPANY PROFILES	200
ACRYMED, INC.....	200
Acrymed, Inc. (Continued)	201
AFFINERGY, INC.....	202
AGION TECHNOLOGIES, INC.....	202
ALEXZA PHARMACEUTICALS.....	203
ALLIED MINDS/BIOTECTIX.....	204
ANGIOTECH PHARMACEUTICALS, INC.....	204
ARROW INTERNATIONAL.....	205
AVITA MEDICAL	206
AXCAN PHARMA, INC.	206
BIND BIOSCIENCES, INC.	207
BIOCOAT, INC.....	208
BIOCOMPATIBLES UK, LTD.	209
BIOHEART, INC.....	210

BIOMET, INC.....	211
BRONCUS TECHNOLOGIES, INC.....	212
CELSION CORPORATION.....	213
CODMAN & SHURTLEFF, INC.....	214
COLLAGEN MATRIX, INC.....	214
COOK MEDICAL, INC.....	214
CORDIS CORPORATION.....	215
COVIDIEN, PLC.....	215
CYNOSURE, INC.....	216
DUSA PHARMACEUTICALS, INC.....	216
EDWARDS LIFESCIENCES CORP.....	217
ENDOVASC, INC.....	217
ETEX CORPORATION.....	218
EXACTECH, INC.....	218
FORTICELL, INC.....	219
INFRAREDIX.....	220
INTEGRA LIFESCIENCES HOLDINGS CORP.....	221
INTERPORE CROSS INTERNATIONAL.....	221
Interpore Cross International (Continued).....	222
ISTA PHARMACEUTICALS.....	223
KENSEY NASH CORPORATION.....	223
KIADIS PHARMA B.V.....	224
LIFECELL CORP.....	225
MARTECH MEDICAL PRODUCTS.....	225
MILLENIUM BIOLOGIX, INC.....	226
MIRAVANT MEDICAL TECHNOLOGIES.....	226
MIV THERAPEUTICS INC.....	227
NOVABONE PRODUCTS, LLC.....	228
NUCRYST PHARMACEUTICALS, INC.....	229
OMRIX BIOPHARMACEUTICALS, LTD.....	230
ORGANOGENESIS, INC.....	231
ORTHOVITA, INC.....	232
PHARMACYCLICS, INC.....	233
PHOTOCURE ASA.....	233
PHOTOBOTICS.....	234
QLT, INC.....	235
SMITH & NEPHEW, PLC.....	235
SORIN S.P.A.....	236
STRYKER CORP.....	236
SURMODICS, INC.....	236
SYNTHES, INC.....	237
SYSTAGENIX WOUND MANAGEMENT.....	238
TEI BIOSCIENCES, INC.....	239
WRIGHT MEDICAL GROUP, INC.....	239

W. L. GORE & ASSOCIATES, INC.....	240
APPENDIX 1: RECENT FDA APPROVALS OF DEVICES, INCLUDING COMBINATION DEVICES	241
<i>TABLE 33 MEDICAL DEVICES APPROVED BY THE FDA, 2009</i>	241
<i>TABLE 34 MEDICAL DEVICES APPROVED BY THE FDA, 2008</i>	242
<i>TABLE 35 MEDICAL DEVICES APPROVED BY THE FDA, 2007</i>	243
APPENDIX 2: GLOSSARY OF RELEVANT TERMINOLOGY	244